Mark Wildgust

Oncology

Mark Wildgust, VP of global medical affairs, oncology, at Johnson & Johnson Innovative Medicine, discusses J&J’s ambition to get in front of cancer.

News

London-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising €575m for "Europe's boldest innovators."

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.